Castuner

Post-Hoc Live

Endpoints News

Post-Hoc Live is an extension of Endpoints' analysis newsletter Post-Hoc — but streamed live on YouTube then brought to you here. Our reporters spend every day texting and calling sources, reading executive orders, and talking to each other in Slack. We're bringing that analysis that happens behind the scenes directly to you, and letting you in on some of our up-to-the-moment conversations.Subscribe to Endpoints and the Post-Hoc newsletter here: https://profile.endpoints.news/create-account. Send us an email at: [email protected]

Podcast website

Listen in your app

Episodes

55 episodes

  1. The US midterm elections and biopharma 43:07
  2. Is biotech’s future full of zero-employee startups? 39:22
  3. Did Treasury’s COINS rule just end China biotech deals? 41:41
  4. Live from DC: Will Congress put a stop to China biotech deals? 24:27
  5. Live from DC: Is secrecy the solution? 26:30
  6. Live from DC: What do we really mean when we talk about biosecurity risk and China? 26:08
  7. Live from DC: Can the FDA steer clinical trials back to the US? 23:17
  8. Live from Boston: How pharma thinks about China 24:04
  9. Live from Boston: Investor math versus industrial priority 45:10
  10. Live from Boston: Has China changed how we build companies? 27:25
  11. The case for — and against — an AZ-BMS megadeal 35:10
  12. Record IPOs — with Parabilis and Kailera’s CEOs 33:54
  13. Are the China hawks winning? 42:22
  14. How much is everyone in biopharma getting paid? 32:38
  15. How to stabilize US biotech — with Dr. Jeremy Levin 32:56
  16. Makary's out: Live from the FT Summit 29:01
  17. Q1 earnings recap with Endpoints News 38:18
  18. Trust, MAHA, and what’s next for the CDC 34:15
  19. The spring deals bonanza 36:39
  20. The politics of vaccines — with former congressman Dr. Michael Burgess 35:11
  21. Who won the Hims vs Novo feud? 28:24
  22. Protecting US biotech from Chinese competition — with the NSCEB 36:06
  23. Moderna vs the FDA 30:03
  24. Hims, Novo, and a new front in the compounding wars 32:17
  25. Post-Hoc Live, Live! at #JPM26 with Noubar Afeyan 27:09
  26. Fewer drugs, more chaos: One year under the new FDA 32:51
  27. Biopharma’s Winners and Losers of 2025 30:31
  28. Reality check-ing biotech — with Derek Lowe 41:34
  29. M&A, MFN, and the view from the UK — with the FT’s Hannah Kuchler 29:01
  30. The plan to make more custom CRISPR therapies — w Kiran Musunuru & Rebecca Ahrens-Nicklas 36:09
  31. The fight over Metsera 31:06
  32. Is the biotech market…back? — with Tim Opler and John Carroll 32:06
  33. Zooming out on AI in biopharma — with Vijay Pande 38:16
  34. This week in Washington: TrumpRx, MFN pricing, tariffs, and more 42:29
  35. Scott Gottlieb on what it would take to compete with China's biotech rise 33:53
  36. Which digital health tools are worth the cost? — with Caroline Pearson 30:52
  37. Breaking down the XBI — with Josh Schimmer 33:00
  38. Choosing the Endpoints 11 32:40
  39. John Maraganore and Clive Meanwell are coming out of stealth 38:01
  40. mRNA vs MAHA — with Brett Giroir 39:58
  41. Getting answers on tariffs, China and Trump: What we learned from Q2 earnings 33:30
  42. Why China’s biotech boom may be unstoppable 35:23
  43. The Sarepta mess 36:50
  44. Sarepta’s very bad week 34:45
  45. Drugs! In! Space! With Varda Chief Science Officer Adrian Radocea 33:18
  46. Is China a threat, or an investment opportunity? Post-Hoc Live with Curie.Bio CEO Zach Weinberg 42:32
  47. What we learned from RFK’s reconstructed ACIP 40:38
  48. On the ground at BIO 2025 32:48
  49. What happens if AI gets smarter than we are? 40:39
  50. The fallout from RFK's gutting of ACIP: Post-Hoc Live with former CDC Director Mandy Cohen 33:27